Italian study to track Real-World use of Next-Gen cholesterol drugs
NCT ID NCT07543731
First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times
Summary
This study will look at how consistently nearly 6,000 adults in Italy take three newer cholesterol-lowering drugs (inclisiran, evolocumab, and alirocumab) over the long term. Researchers will analyze prescription records to measure adherence and persistence in everyday medical practice. The goal is to understand real-world usage patterns, not to test the drugs' effectiveness or safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATHEROSCLEROTIC CARDIOVASCULAR DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis
RECRUITINGBasel, CH-4056, Switzerland
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can better healthcare access save hearts after prison?
- Can lifestyle choices after a stroke extend life and prevent a second one?
- Could a simple health chat slash heart disease and cancer risk?
- One scan, many answers: can a new CT predict heart risks after stenting?
- Digital coaching aims to boost heart health in obesity
- Can a new device suck out deadly lung clots?